Print View

Your printed page will look something like this.

Kevin K. Wang


Session Title:

Prediction of Recovery from Mild to Moderate TBI


Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver in 1989. He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and following the company’s merger with Pfizer Inc. (2000), he became Group Leader of CNS Therapeutics/CNS new targets team. He also co-chaired the Far East Scientific Opportunity Team. In 2002, he became Associate Professor of Psychiatry at the University of Florida (Gainesville, FL), Associate Director of the Center for Traumatic Brain Injury Studies and Director of the Center of Neuroproteomics and Biomarkers Research. In 2002, he is a Founder of biotechnology company Banyan Biomarkers Inc. (Alachua, Florida). In 2007, he transitioned to Banyan as full-time Chief Scientific Officer and the Center Director of the Center of Innovative Research. . Dr. Wang has contributed significantly to the discovery, sensitive sandwich ELISA development of two acute TBI protein biomarkers (UCH-L1 and GFAP-BDP) and their diagnostic utility characterization in several animal and human TBI spectrum studies. This TBI biomarker tandem is now in pivotal study for FDA approval as a new first-in-class in vitro diagnostic (IVD) test for mild-moderate TBI (ALERT Trial). In 2011, he rejoined the University of Florida McKnight Brain Institute as Executive Director of the Center of Neuroproteomics and Biomarkers Research /Chief – Translational Research & Associate Professor of Psychiatry and Neuroscience and to rededicate himself to basic and translational research. He is also Chair Professor of the Taipei Medical University.